Role of chemotherapy in relapsed ovarian cancer (Q33816593)

29 July 2017

1 reference

title

Role of chemotherapy in relapsed ovarian cancer (English)

1 reference

29 July 2017

1 reference

Colombo N

1

1 reference

29 July 2017

Parma G

2

1 reference

29 July 2017

Bocciolone L

3

1 reference

29 July 2017

Sideri M

4

1 reference

29 July 2017

Franchi D

5

1 reference

29 July 2017

Maggioni A

6

1 reference

29 July 2017

publication date

1 December 1999

1 reference

Critical Reviews in Oncology Hematology

29 July 2017

published in

1 reference

29 July 2017

volume

32

1 reference

29 July 2017

issue

3

1 reference

29 July 2017

page(s)

221-228

1 reference

Phase II trial of paclitaxel in patients with progressive ovarian carcinoma after platinum-based chemotherapy: a Gynecologic Oncology Group study.

29 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2899%2900049-9

7 January 2021

Paclitaxel for platinum-refractory ovarian cancer: results from the first 1,000 patients registered to National Cancer Institute Treatment Referral Center 9103.

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2899%2900049-9

7 January 2021

Taxol: a unique antineoplastic agent with significant activity in advanced ovarian epithelial neoplasms

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2899%2900049-9

7 January 2021

Phase II study and long-term follow-up of patients treated with taxol for advanced ovarian adenocarcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2899%2900049-9

7 January 2021

Response of patients in phase II studies of chemotherapy in ovarian cancer: implications for patient treatment and the design of phase II trials

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2899%2900049-9

7 January 2021

Treatment of relapsed carcinoma of the ovary with cisplatin or carboplatin following initial treatment with these compounds

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2899%2900049-9

7 January 2021

Predictors of response to subsequent chemotherapy in platinum pretreated ovarian cancer: A multivariate analysis of 704 patients

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2899%2900049-9

7 January 2021

Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for stage III ovarian cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2899%2900049-9

7 January 2021

Recurrent ovarian carcinoma: retreatment utilizing combination chemotherapy including cis-diamminedichloroplatinum in patients previously responding to this agent

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2899%2900049-9

7 January 2021

Second-line platinum therapy in patients with ovarian cancer previously treated with cisplatin

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2899%2900049-9

7 January 2021

Salvage chemotherapy for ovarian cancer recurrence: weekly cisplatin in combination with epirubicin or etoposide

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2899%2900049-9

7 January 2021

Carboplatin and cyclophosphamide salvage therapy for ovarian cancer patients relapsing after cisplatin combination chemotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2899%2900049-9

7 January 2021

Relationships between carboplatin exposure and tumor response and toxicity in patients with ovarian cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2899%2900049-9

7 January 2021

High-dose carboplatin in refractory ovarian cancer patients.

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2899%2900049-9

7 January 2021

Responses to second-line cisplatin-based intraperitoneal therapy in ovarian cancer: influence of a prior response to intravenous cisplatin

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2899%2900049-9

7 January 2021

Response to salvage treatment in recurrent ovarian cancer treated initially with paclitaxel and platinum-based combination regimens

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2899%2900049-9

7 January 2021

Salvage chemotherapy for epithelial ovarian carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2899%2900049-9

7 January 2021

Second-line chemotherapy for recurrent carcinoma of the ovary.

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2899%2900049-9

7 January 2021

Phase II study of intravenous topotecan as a 5-day infusion for refractory epithelial ovarian carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2899%2900049-9

7 January 2021

Topotecan versus paclitaxel for the treatment of recurrent epithelial ovarian cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2899%2900049-9

7 January 2021

Docetaxel: an active new drug for treatment of advanced epithelial ovarian cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2899%2900049-9

7 January 2021

Phase II trial of docetaxel in patients with platinum-refractory advanced ovarian cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2899%2900049-9

7 January 2021

Single agent activity of oxaliplatin in heavily pretreated advanced epithelial ovarian cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2899%2900049-9

7 January 2021

Phase II study of liposomal doxorubicin in refractory ovarian cancer: antitumor activity and toxicity modification by liposomal encapsulation.

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2899%2900049-9

7 January 2021

Oral etoposide is active against platinum-resistant epithelial ovarian cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2899%2900049-9

7 January 2021

Prolonged oral etoposide as second-line therapy for platinum-resistant and platinum-sensitive ovarian carcinoma: a Gynecologic Oncology Group study

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2899%2900049-9

7 January 2021

Phase II study of prolonged oral etoposide in refractory ovarian cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2899%2900049-9

7 January 2021

Hexamethylmelamine as a single second-line agent in ovarian cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2899%2900049-9

7 January 2021

Hexamethylmelamine in ovarian cancer after failure of cisplatin-based multiple-agent chemotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2899%2900049-9

7 January 2021

Hexamethylmelamine chemotherapy for persistent or recurrent epithelial ovarian cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2899%2900049-9

7 January 2021

Phase II trial of ifosfamide and mesna in advanced ovarian carcinoma: a Gynecologic Oncology Group Study

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2899%2900049-9

7 January 2021

Ifosfamide and mesna in previously treated advanced epithelial ovarian cancer: activity in platinum-resistant disease

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2899%2900049-9

7 January 2021

A randomised study of carboplatin vs sequential ifosfamide/carboplatin for patients with FIGO stage III epithelial ovarian carcinoma. The London Gynaecologic Oncology Group.

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2899%2900049-9

7 January 2021

High-dose ifosfamide: circumvention of resistance to standard-dose ifosfamide in advanced soft tissue sarcomas

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2899%2900049-9

7 January 2021

Phase II study of vinorelbine in patients with pretreated advanced ovarian cancer: activity in platinum-resistant disease

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2899%2900049-9

7 January 2021

Phase II trial of vinorelbine in recurrent and progressive epithelial ovarian cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2899%2900049-9

7 January 2021

A phase I study of a daily x3 schedule of intravenous vinorelbine for refractory epithelial ovarian cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2899%2900049-9

7 January 2021

Tamoxifen in platinum-refractory ovarian cancer: a Gynecologic Oncology Group Ancillary Report

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2899%2900049-9

7 January 2021

Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2899%2900049-9

7 January 2021

10.1016/S1040-8428(99)00049-9

Identifiers

DOI

1 reference

29 July 2017

1 reference